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ORIGINAL ARTICLE
Tuberculosis (TB) remains a significant worldwide
problem and is responsible for extensive mor-
bidity and mortality. The World Health Organiza-
tion (WHO) has estimated that one-third of the
population worldwide is infected with TB. The
estimated incidence of TB in 2002 was 8.8 million
cases.1 TB is the second most common infectious
cause of adult mortality and is ranked 10th of all
causes of loss of a healthy life world-wide.1 The
highest rates are in Southeast Asia, sub-Saharan
Africa and Eastern Europe.
Mycobacterium tuberculosis bacteremia (MTB)
was first documented by Faber in 1914.2 Clough
reported five patients with MTB bacteremia in
Mycobacterium tuberculosis Bacteremia in
HIV-negative Patients
Yu-Shin Chiu,1,2 Jann-Tay Wang,2,3 Shan-Chwen Chang,2,3,4 Jih-Luh Tang,5 Shih-Chi Ku,6
Chien-Ching Hung,2 Po-Ren Hsueh,7 Yee-Chun Chen2,3.4*
Background/Purpose: Limited information exists about the epidemiologic characteristics of HIV-negative
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radiologic findings and therapy were collected. Long-term outcome was evaluated at 1 year after initiation of
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Results: During the study period the incidence of MTB bacteremia in HIV-negative patients and HIV-positive
patients were 0.024 and 6.2 per 1000 discharges, respectively (p < 0.01). All 11 HIV-negative patients were
males and eight (73%) were more than 50 years old. The most common underlying diseases/conditions
were immunosuppressive therapy (64%) and heart disease (55%). Fever (80%), lymphopenia (75%) and
pulmonary symptoms (58%) were the most common presentations. Ten patients were septic, two had septic
shock and two had acute respiratory distress syndrome on admission. The median interval between admis-
sion and initiation of therapy for those who were cured was 6 days. Six (55%) died of TB and/or their under-
lying diseases. Of the six patients who died, the median survival after collection of positive blood culture
was 19 days for three treated patients and 7 days for three untreated patients (p = 0.01).
Conclusion: This case series demonstrates the wide spectrum of the initial presentation of HIV-negative
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19173 and Shapira reported another seven pa-
tients in 1932.4 During the past two decades, the
diagnosis of mycobacteremia has been made with
increasing frequency.5 This appears to be due to
increased awareness following the HIV epidemic
and the availability of new culture systems for the
rapid detection of mycobacteremia. These meth-
ods include the lysis-centrifugation system and
radiometric culture broth methods.5 The incidence
of MTB bacteremia is much higher in HIV-positive
patients than HIV-negative patients (79–100% vs.
0–21%).6–8 MTB bacteremia is well described in
acquired immunodeficiency syndrome (AIDS)
but not in HIV-negative patients.9 To better under-
stand the clinical manifestations and outcome of
MTB bacteremia in HIV-negative patients, we re-
viewed 11 cases hospitalized at our institution
during 1997–2003 and 16 described in the litera-
ture during 1967–2004.
Methods
Hospital setting
National Taiwan University Hospital (NTUH) is
a 2000-bed teaching hospital in northern Taiwan.
It offers both primary and tertiary medical care
services. During the study period, HIV status was
routinely checked in all TB cases and at least three
sputum specimens were tested for pulmonary TB.
According to the regulation, all newly diagnosed
TB patients should be reported to the local health
department. Infection control persons in this hos-
pital play an important role by helping physi-
cians in the process of identification and report
and maintain the database. We surveyed all culture
positive TB cases reported between January 1997
and December 2003. The medical records of all
the patients from whom MTB was isolated from
the blood or bone marrow were retrospectively re-
viewed. HIV-positive patients were excluded from
the analysis.
Data collection
A standardized case record form was used to collect
the following data: age, gender, underlying diseases,
immunosuppressive therapy, clinical presentation,
radiologic findings, isolation of MTB from clini-
cal specimens, therapy and outcome. Patients who
were lost to follow-up or who died were censored
at the time of the last clinic visit or date of death.
Long-term outcome was evaluated at 1 year after
initiation of anti-TB agents.
Definition
Sepsis, septic shock and multi-organ failure 
were defined according to the classification of the
American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference.10
Cure was defined as no relapse or recurrence after
completion of treatment for 1 year up to the last
clinic visit.
Mycobacterial culture and identification
Blood cultures for MTB were not included in rou-
tine practice during the study period. Blood cul-
tures for MTB were obtained from patients with
sepsis or persistent high fever of unknown origin
(FUO). Despite antibacterial therapy, some were
suspected of having TB by one of the authors. Up
to 5 mL of blood was collected in ethylenediamine
tetraacetic acid (EDTA) or heparin-containing
tubes and processed by a noncommercial lysis-
centrifugation method as described earlier.11 The
tube was centrifuged and the sediment was inoc-
ulated onto Lowenstein-Jensen medium (BBL,
Becton Dickinson, Sparks, MD, US), Middlebrook
7H9 broth and 7H11 agar plates (BBL, Becton
Dickinson). The BACTEC MGIT 960 system (Becton
Dickinson) was added after July 1998. The cultures
were incubated at 35°C in 5% CO2 for up to 
8 weeks. Colonies growing on agar paddles or
Middlebrook agar were defined as suspected 
mycobacteria by acid-fast stain. The species of
Mycobacterium was identified according to the
standard criteria.12
Review of the literature
MTB bacteremia in HIV-negative patients described
in the English literature between 1967 and 2004
were identified using a MEDLINE (National Library
of Medicine, Bethesda, MD) search cross-referencing
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the key words Mycobacterium tuberculosis and bac-
teremia. Review of the reference lists of each article
identified additional cases. Reports were excluded
either when HIV infection was an underlying con-
dition or patients without AIDS could not be dis-
tinguished from those with HIV. The underlying
diseases and clinical manifestations were reported
in some of the reference cases from the literature.
Statistical analysis
Categorical variables were compared using Fisher’s
exact test. Continuous variables were compared
using Mann–Whitney U test. The statistical analyses
were carried out using SPSS version 10.0 (SPSS Inc.,
Chicago, IL, USA) for Windows. Variables of inci-
dence density were compared using normal theory
test and calculated manually. A p value < 0.05 was
considered significant.
Results
Experience at NTUH during 1997–2003
Incidence of MTB
A total of 6128 patients with TB were reported at
NTUH during the study period. Of 1971 patients
(1971/6128, 32.1%) with culture positive for MTB,
19 patients had MTB isolated from blood or bone
marrow (19/1971, 0.096%) among the 469,306
patients discharged from NTUH (0.04 per 1000
discharges). The incidence of MTB bacteremia in
HIV-positive patients (eight cases) and HIV-neg-
ative patients (11 cases) were 6.2 and 0.024 per 
1000 discharges, respectively (p < 0.01). The inci-
dence of MTB in HIV-negative patients increased
from 0.02 in 1997 to 0.06 cases/1000 discharges
in 2003 (p = 0.286).
Demographic and clinical characteristics of 
HIV-negative patients with MTB bacteremia
All were male patients and eight (72.7%) of them
were above 50 years of age. All had underlying
diseases, including heart disease, malignancies,
autoimmune diseases, chronic liver disease and
end-stage renal disease (Table 1). Seven patients
(63.6%) received glucocorticosteroids or other
immunosuppressive drugs (Table 2). In addition,
patient 3 had idiopathic CD4 lymphocytopenia
(< 400 cells/μL). The most common clinical man-
ifestation was fever (Table 1). Six patients had fever
for 3 weeks or longer (Table 2). Ten patients were
septic, two had septic shock and two had acute res-
piratory distress syndrome (ARDS) on admission.
Eight patients had abnormal chest radiographs.
These included miliary patterns (three patients),
nonspecific infiltrates (two patients), pleural effu-
sion (two patients), multiple patches of consoli-
dation (one patient) and a cavity (one patient). All
three patients with miliary pattern on chest radi-
ographs were diagnosed premortem, but only
four of the eight patients without miliary pattern
on chest radiographs were diagnosed premortem
(100% vs. 50%, p = 0.2).
Lymphopenia (< 1000 cells/mL3) was the most
common laboratory finding at admission (9 pa-
tients). Blood culture was the only sample yielding
MTB in two patients. MTB was also isolated from
sputum, bronchial washing, pleural effusion or
lung tissue (10 patients), bone marrow (5),
lymph node (2), synovial fluid (2), ascites fluid
(2), urine (2) and stool (1). The median inter-
vals from collection of blood cultures to identifi-
cation of MTB was 36 days (range, 21–72 days).
Nine of the 11 isolates of MTB were susceptible
to all first line agents (isoniazid, rifampin, ethamb-
utol and streptomycin), one isolate was resistant
to streptomycin, and one isolate was resistant to
isoniazid, rifampin, and streptomycin.
Treatment and outcome
Eight of the 11 patients (72.7%) received anti-TB
therapy. Seven received four-combined anti-TB
therapy (isoniazid, ethambutol, rifampin, pyraz-
inamide) within a median of 6 days (range, 1–31
days) after admission. Direct microbiologic evi-
dence of MTB (acid-fast stain and/or nucleic acid
amplification by polymerase chain reaction) was
found in four of these seven patients (Table 3).
Three patients were treated presumptively because
TB was highly suspected clinically. An additional
patient was treated with ethambutol, streptomycin
and ciprofloxacin initially for Mycobacterium 
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abscessus isolated from sputum prior to identifica-
tion of co-infection with MTB. Three patients (27%)
did not receive anti-TB therapy because there was
no clinical evidence of MTB infection, acid-fast
stains of all specimens were negative, and an alter-
native diagnosis was made (fungal pneumonia
in patient 1, bacterial infection in patient 8, and
pulmonary metastasis in patient 11). All these three
patients died due to multiple organ failure.
Among eight patients who received anti-TB
therapy, five patients were cured after treatment for
at least 12 months. The median interval between
admission and initiation of anti-TB therapy for
those who were cured was 6 days (range, 1–31
days). Eight of the 11 (72.7%) patients developed
septic shock and/or adult respiratory distress syn-
drome and six (54.5%) died of TB and/or their un-
derlying diseases. Of the six patients who died, the
median survival after collection of positive blood
culture was 19 days (range, 17–25 days) for three
treated patients and 7 days (range, 1–9 days) for
three untreated patients (p = 0.01).
Review of the literature
A total of 16 HIV-negative patients with MTB bac-
teremia with detailed clinical information were
identified in the English literature between 1971
and 2004. These included eight cases reported from
Table 1. Demographic and clinical characteristics and outcome in 27 HIV-negative patients with
Mycobacterium tuberculosis bacteremia
Cases in the 
Current series literature6,7,13–20 Total 
1997–2003 (n = 11) 1971–2004 (n = 16) (n = 27)
n* (%) n (%) n (%)
Demographic characteristics
Age, yr (mean ± SD) 57.2 ± 14.6 51.3 ± 19.6 54.9 ± 16.4
Male:female 11:0 9:6 20:6
Underlying diseases or conditions
Heart diseases 6/11 (54.5) 4/11 (36.4) 10/22 (45.5)
Malignancy or transplantation 4/11 (36.4) 0/11 (0) 4/22 (18.2)
Autoimmune diseases† 3/11 (27.2) 1/11 (9.1) 4/22 (18.2)
Liver diseases 1/11 (9.1) 1/11 (9.1) 2/22 (9.1)
Renal diseases 1/11 (9.1) 0/11 (0) 1/22 (4.5)
Others 0/11 (0) 1/11 (9.1) 1/22 (4.5)
None 0/11 (0) 4/11 (36.4) 4/22 (18.2)
Presentations
Fever (> 38°C) 8/11 (72.7) 12/14 (85.7) 20/25 (80.0)
Pulmonary symptoms (cough, dyspnea) 8/11 (72.7) 7/15 (46.7) 15/26 (57.7)
Weight loss or cachexia 5/11 (45.4) 2/16 (12.5) 7/27 (25.9)
Diarrhea (persisted for 3 d) 4/11 (36.3) NA NA
Synovitis 2/11 (18.1) NA NA
Lymphocytopenia (< 1000 cells/mL3) 9/11 (81.8) 3/5 (60.0) 12/16 (75.0)
Lymphadenopathy 4/11 (36.3) 1/5 (20.0) 5/16 (31.2)
Hepatomegaly or splenomegaly 3/11 (27.2) NA
Pulmonary lesions on X-ray 8/11 (72.7) 12/16 (75.0) 20/27 (74.0)
Miliary lesions 3/11 (27.2) 2/16 (12.5) 5/27 (18.5)
Death 6/11 (54.5) 6/16 (37.5) 12/27 (44.4)
*Number of patients evaluated or data available; †all received glucocorticosteroid therapy. SD = standard deviation; NA = not available.
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Spain, six from United States of America, and two
from Brazil.6,7,13–20 The demographic and clinical
characteristics of these 16 patients together with
the 11 patients in the current series are summarized
in Table 1. In both series, males predominated,
heart disease was the most common underlying
disease and fever was the leading presentation.
However, 36.4% of the 16 patients described in the
literature did not have any underlying disease. In
the current series, all the patients had an under-
lying disease and most of the patients were se-
verely immunocompromised by their underlying
disease or therapy.
Discussion
Incidence
In the United States, the incidence of TB had in-
creased steadily between 1985 and 1992.21 This
was followed by a resurgence of interest in TB 
associated with the AIDS epidemic. After 1992,
the incidence declined and was 5.2 cases per
100,000 in 2002.21 Taiwan remains an endemic
area for TB (64.8 cases/100,000 in 2001).22
During 1998–2002, the most specialized TB hos-
pitals in Taiwan were closed. More TB patients
are now being managed in general hospitals 
including NTUH. The numbers of newly diag-
nosed culture positive TB increased from 139 
in 1998 (2.39 cases/1000 discharges) to 380 in
2002 (4.85/1000 discharges) at NTUH23 and in
concordance to the trend for an increase in the
incidence of MTB bacteremia in the current series.
The increasing diagnosis of MTB bacteremia may
also result from an improved awareness of TB and
an increase in susceptible immunocompromised
patients.
Underlying conditions
Up to 72.7% of patients in the current series were
>50 years of age. In Europe, 80% of MTB-infected
persons are >50 years of age.24 An increased inci-
dence of TB is associated with advanced age in
Southeast Asia, Europe and the United States.24,25
Risk factors for reactivation of TB in the elderly
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include age, diabetes mellitus, chronic renal fail-
ure, gastrectomy, hematologic malignancies and
other cancers as well as waning immunity of 
diverse causes.25
Predisposing conditions for patients with 
disseminated TB include HIV infection (46%),
immunosuppressive therapy (21%), alcoholism
(12%), and hematologic disorders (8%).26 Of 19
patients with MTB bacteremia diagnosed at NTUH,
the most common predisposing condition was HIV
infection (eight cases, 42%) followed by immuno-
suppressive therapy (seven cases, 37%). Two pa-
tients in our case series were hematopoietic stem
cell transplantation (HSCT) recipients and both
died. In a previous study, we found that the relative
risk of pulmonary TB after HSCT was 13-fold
higher than in the general population.27 Two of the
eight HSCT recipients (25%) with pulmonary TB
had positive cultures from either blood or bone
marrow. One patient in our series had chronic renal
failure. This patient was afebrile and died without
treatment. The rates of TB in end-stage renal failure
are 10- to 25-fold greater than those in the general
population.28 Heart disease is quite common in
HIV-negative patients with MTB bacteremia both
in the literature and our case series. The reason
remains to be elucidated.
Clinical presentations
This case series demonstrates the wide spectrum
of the initial presentation of MTB bacteremia,
which ranged from afebrile to prolonged fever or
FUO, and from mild infection to sepsis, septic
shock and/or ARDS. TB is the most common causes
of infection in patients with FUO in Taiwan.29,30
The proportion of FUO due to TB increased from
8% in 1974, 10.6% during 1986–1989, to 14%
during 1999–2002 at NTUH30 and up to 23% in
a prospective study in Southern Taiwan.29 Thus,
TB should be included in the differential diagnosis
of FUO or sepsis of unknown source who fail to
respond to empirical broad-spectrum antibiotic
and/or antifungal therapy in the elderly and im-
munocompromised patients.
Only one of 11 isolates in the current case 
series was multi-drug-resistant (MDR) (resistant
to both isoniazid and rifampin). In Taiwan, the
mortality rate for patients with TB is 8.9%.22 At
NTUH, the case fatality rate was 8.2% for patients
with non-MDR strains, 23% for those with MDR
strains23 and 9.8% for adult patients with cul-
ture-proven TB meningitis.31 The case fatality rate
was much higher for HIV-negative patients with
MTB bacteremia (54.5% in current series and
37.5% in the literature) and was likely due to the
severity of illness (septic shock and/or ARDS),
immunocompromised status (63.6%) and no
anti-TB treatment (27.3%) in the current series.
Our previous study showed that of the 825 pa-
tients with active pulmonary TB, inhospital mor-
tality rate was up to 65.9% as 41 patients suffered
acute respiratory failure.32 This also reflects the
difficulty in making a diagnosis and the limitation
of current diagnostic approaches.
Diagnostic approaches
There needs to be an increased awareness of 
TB, aggressive pursuit of a histopathologic diagno-
sis (bone marrow, lymph nodes, lung/pleura),33
blood cultures and application of rapid and sen-
sitive diagnostic tests for TB (including nucleic
acid amplification tests). The diagnosis of dissem-
inated TB is often difficult because of its nonspe-
cific clinical presentation25,26,33–35 and difficulty in
collecting adequate sputum samples in the elderly
and immunocompromised patients. In addition,
thrombocytopenia from chemotherapy may pre-
clude or delay invasive diagnostic procedures.35
MTB bacteremia was common in high-risk popu-
lations with TB.6,26 When tested, 14% of culture-
proven TB had MTB isolated from blood6 and
58% of disseminated TB had MTB bacteremia.26
The latter study also demonstrated that mycobac-
terial blood culture contributed to the diagnosis
of disseminated TB in 17% of cases during the
1980s and that this increased to 47% during the
1990s.26 In the current series, blood was the only
positive specimen in two of the 11 patients. Thus,
mycobacterial blood culture can play an increas-
ing role in the diagnosis of disseminated TB when
localized disease is not found or specimens for
the infected site are not available. Furthermore,
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nucleic acid amplification tests on blood can
confirm the diagnosis within 24 hours in one
third of the cases with MTB bacteremia.36,37 Thus,
blood for MTB culture and/or nucleic acid ampli-
fication should be included in diagnostic proce-
dures of FUO and sepsis of unknown source who
fail to response to empirical broad-spectrum
antibiotic and/or antifungal therapy in the elderly
and immunocompromised patients in endemic
regions.27,35,38
Limitations of the current study
This case series, though a retrospective study, pro-
vided comprehensive information. Each patient
was evaluated by at least one of the authors because
of persistent fever despite potent antibacterial and/
or antifungal therapy or difficulty in making de-
cisions. Nevertheless there are several limitations
to this study. First, mycobacterial blood culture in
HIV-negative patients was performed only when
a consultant in infectious diseases suspected dis-
seminated TB. A prospective study in Taiwan
demonstrated that one in 27 newly diagnosed pa-
tients with TB had bacteremia (3.7%).38 Thus, the
incidence of MTB bacteremia in the current series is
underestimated. Second, this study probably un-
derestimated the incidence of MTB bacteremia in
other parts of Taiwan where TB is more endemic
than in Taipei city.29,30,39 Third, not all cases repor-
ted in the literature were analyzed but only those
with detailed clinical information were reviewed.
In conclusion, this case series demonstrated
the wide spectrum of the initial presentation of
HIV-negative patients with MTB. The case fatality
rate was high and was likely due to immuno-
compromised status and no anti-TB treatment
prior to death. There should be a high index of
suspicion for TB in the elderly, patients receiving
immunosuppressant therapy and those with heart
disease, who have prolonged fever or sepsis of un-
known source, lymphopenia and abnormal chest
radiographs. Blood and/or bone marrow for
MTB cultures combined with vigorous attempts
to make a tissue diagnosis and use of rapid diag-
nostic tests offer the best chance to make an early
diagnosis.
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